Fosmanogepix treatment for coccidioidomycosis under an expanded access program

Area of Science:

• Mycology
• Infectious Diseases
• Clinical Pharmacology

Background:

• Coccidioidomycosis is a serious invasive fungal infection with potential for dissemination.
• Limited effective treatment options exist for severe or disseminated cases.

Purpose of the Study:

• To evaluate the safety and efficacy of fosmanogepix (gepix) in patients with Coccidioidomycosis.
• To assess gepix in both meningeal and non-meningeal disseminated forms of the infection.

Main Methods:

• Expanded access study (NCT06433128) using fosmanogepix.
• Treatment outcomes were assessed in patients with invasive Coccidioidomycosis.

Main Results:

• Fosmanogepix demonstrated success in 8 out of 11 patients.
• Efficacy was observed in 75% of meningitis cases (6/8) and 66% of non-meningeal disseminated cases (2/3).
• The drug was well tolerated over a median treatment duration of 208 days.

Conclusions:

• Fosmanogepix represents a potentially valuable therapeutic option for invasive Coccidioidomycosis.
• The drug shows promising efficacy and good tolerability in a challenging fungal infection.